help button home button
AJRCMB
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Varsano, S.
Right arrow Articles by Radnay, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Varsano, S.
Right arrow Articles by Radnay, J.

Am. J. Respir. Cell Mol. Biol., Volume 19, Number 3, September, 1998 522-529

Cytokines Modulate Expression of Cell-Membrane Complement Inhibitory Proteins in Human Lung Cancer Cell Lines

Shabtai Varsano, Ludmila Rashkovsky, Hava Shapiro, and Judith Radnay

Department of Pulmonary Medicine, Laboratory of Respiratory Cell Biology, and Laboratory of Hematology, Sapir Medical Center, Meir General Hospital, Kfar-Sava; and Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel

Human lung cancers overexpress several cell-membrane complement inhibitory proteins (CIP). These complement inhibitory proteins are membrane cofactor protein (CD46), decay-accelerating factor (DAF; CD55), and CD59 (protectin). These cell-membrane proteins have a wide normal tissue distribution, are known to protect normal host cells from homologous complement-mediated lysis, and are thought to facilitate tumor escape from immunosurveillance. To study whether proinflammatory cytokines that are involved in cancer growth can modulate cell-membrane CIP expression in lung cancer cells, we studied the effect of interleukin (IL)-1alpha , tumor necrosis factor (TNF)-alpha , and interferon (IFN)-gamma on two human lung cancer cell lines. ChaGo K-1 and NCI-H596 cell lines, undifferentiated carcinoma and lung adenosquamous carcinoma, respectively, were stimulated with different cytokines, and the effects of incubation time and cytokine concentration on cell-membrane CIP expression were studied. Cell-membrane CIP expression was evaluated using flow cytometry and cytokine effect was calculated as percent change in mean fluorescence intensity of each CIP molecule from its untreated control. We found that DAF was the lung cancer cell-membrane CIP molecule that was the most responsive to cytokine stimulation. Maximal stimulatory effect was usually noted 72 h after a cytokine was introduced. In ChaGo K-1 and NCI-H596 lung cancer cell lines, IL-1alpha and TNF-alpha increased DAF expression. IL-1alpha (100 U/ml/72 h) increased DAF expression up to a maximal mean of 45 and 48%, respectively, in comparison with untreated cells. TNF-alpha (1,000 U/ml/72 h) increased DAF expression up to a mean of 131 and 46%, respectively. IFN-gamma (1 U/ml/72 h) increased DAF expression in NCI-H596 cells up to a mean of 100%, but had a slight inhibitory effect on DAF expression in ChaGo K-1 cells, decreasing expression by a mean of 17% in comparison with untreated cells. We conclude that cell-membrane DAF expression in the studied human lung cancer cell lines is modulated by IL-1alpha , TNF-alpha , and IFN-gamma , and speculate that cytokine-mediated modulation of cell-membrane DAF in human lung cancer cells might affect lung cancer cell biology.




This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
M. Higuchi, Y. Endo, H. Suzuki, F. Osuka, Y. Shio, K. Fujiu, R. Kanno, A. Oishi, T. Fujita, and M. Gotoh
Identification of the Decay-Accelerating Factor CD55 as a Peanut Agglutinin-Binding Protein and Its Alteration in Non-Small Cell Lung Cancers.
Clin. Cancer Res., November 1, 2006; 12(21): 6367 - 6372.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
V. R. Holla, D. Wang, J. R. Brown, J. R. Mann, S. Katkuri, and R. N. DuBois
Prostaglandin E2 Regulates the Complement Inhibitor CD55/Decay-accelerating Factor in Colorectal Cancer
J. Biol. Chem., January 7, 2005; 280(1): 476 - 483.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
S. L. Young, B. A. Lessey, M. A. Fritz, W. R. Meyer, M. J. Murray, P. L. Speckman, and B. J. Nowicki
In Vivo and in Vitro Evidence Suggest That HB-EGF Regulates Endometrial Expression of Human Decay-Accelerating Factor
J. Clin. Endocrinol. Metab., March 1, 2002; 87(3): 1368 - 1375.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Chen, T. Caragine, N.-K. V. Cheung, and S. Tomlinson
CD59 Expressed on a Tumor Cell Surface Modulates Decay-accelerating Factor Expression and Enhances Tumor Growth in a Rat Model of Human Neuroblastoma
Cancer Res., June 1, 2000; 60(11): 3013 - 3018.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
S. Varsano, M. Kaminsky, M. Kaiser, and L. Rashkovsky
Generation of complement C3 and expression of cell membrane complement inhibitory proteins by human bronchial epithelium cell line
Thorax, May 1, 2000; 55(5): 364 - 369.
[Abstract] [Full Text]

Home page
 J. Virol.Home page
D. R. Shafren, J. Gardner, V. H. Mann, T. M. Antalis, and A. Suhrbier
Picornavirus Receptor Down-Regulation by Plasminogen Activator Inhibitor Type 2
J. Virol., September 1, 1999; 73(9): 7193 - 7198.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Crit. Care Med.
Copyright © 1998 American Thoracic Society. 		  ATS Best of the Web